Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Buys $46,040.00 in Stock

Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Ian Clements bought 4,000 shares of the business’s stock in a transaction on Friday, September 6th. The shares were bought at an average cost of $11.51 per share, for a total transaction of $46,040.00.

Shares of MIRM traded down $0.05 during trading hours on Wednesday, hitting $10.13. 3,576 shares of the stock were exchanged, compared to its average volume of 45,832. Mirum Pharmaceuticals has a fifty-two week low of $9.25 and a fifty-two week high of $15.50. The business’s 50-day simple moving average is $13.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 28th. The company reported ($2.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($1.83). On average, equities research analysts anticipate that Mirum Pharmaceuticals will post -2.14 EPS for the current fiscal year.



A number of equities analysts have recently issued reports on the company. Roth Capital assumed coverage on Mirum Pharmaceuticals in a research report on Monday, August 12th. They set a “buy” rating and a $33.00 price objective for the company. Guggenheim started coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued a “buy” rating and a $18.00 price objective on the stock. Raymond James started coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued an “outperform” rating and a $28.00 price objective on the stock. Evercore ISI initiated coverage on shares of Mirum Pharmaceuticals in a research report on Monday, August 12th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Citigroup initiated coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They set a “buy” rating and a $21.00 price target for the company. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $25.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Featured Article: Oversold

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.